The promise of a prophylactic Epstein–Barr virus vaccine

Henry H. Balfour, David O. Schmeling, Jennifer M. Grimm-Geris

Research output: Contribution to journalReview article

1 Scopus citations

Abstract

The worldwide burden of disease due to Epstein–Barr virus (EBV) infection is enormous. Diseases include endemic Burkitt lymphoma, infectious mononucleosis, cancers after transplantation, Hodgkin lymphoma, and nasopharyngeal carcinoma. A prophylactic EBV vaccine has the potential to significantly reduce the incidence and/or the severity of all these diseases. Infectious mononucleosis can be nasty and prolonged with a median duration of 17 days. Patients, especially children, undergoing bone marrow or solid organ transplantation may develop post-transplant lymphoproliferative disorder (PTLD). Preventing or modifying primary EBV infection could reduce the incidence PTLD, and also certain lymphomas and nasopharyngeal carcinoma. EBV is a major environmental risk factor for multiple sclerosis (MS). Contracting EBV is essential to getting MS, and having a childhood case of infectious mononucleosis increases that risk. Vaccinating against EBV could be vaccinating against MS.

Original languageEnglish (US)
Pages (from-to)345-352
Number of pages8
JournalPediatric Research
Volume87
Issue number2
DOIs
StatePublished - Jan 1 2020

    Fingerprint

PubMed: MeSH publication types

  • Journal Article
  • Review
  • Research Support, Non-U.S. Gov't

Cite this